🙌 That’s a wrap on #ESMO25!
EORTC shared new results and future trials focused on patient needs, long-term outcomes & treatment optimisation.
Thanks to all collaborators and patients who make this work possible.
🔗 Full summary: www.eortc.org/blog/2025/10...
#CancerResearch #ClinicalTrials
EORTC shared new results and future trials focused on patient needs, long-term outcomes & treatment optimisation.
Thanks to all collaborators and patients who make this work possible.
🔗 Full summary: www.eortc.org/blog/2025/10...
#CancerResearch #ClinicalTrials
October 21, 2025 at 7:38 AM
🙌 That’s a wrap on #ESMO25!
EORTC shared new results and future trials focused on patient needs, long-term outcomes & treatment optimisation.
Thanks to all collaborators and patients who make this work possible.
🔗 Full summary: www.eortc.org/blog/2025/10...
#CancerResearch #ClinicalTrials
EORTC shared new results and future trials focused on patient needs, long-term outcomes & treatment optimisation.
Thanks to all collaborators and patients who make this work possible.
🔗 Full summary: www.eortc.org/blog/2025/10...
#CancerResearch #ClinicalTrials
🧠 Great exchange at our EANO Youngsters - EORTC Joint session at #EANO2025!
🚀 We discussed how collaboration through EORTC supports early-career investigators - and vice versa - plus insights into current brain tumor trials.
Thanks @eortc.org & @eanoassociation.bsky.social!
#NeuroOncology #btsm
🚀 We discussed how collaboration through EORTC supports early-career investigators - and vice versa - plus insights into current brain tumor trials.
Thanks @eortc.org & @eanoassociation.bsky.social!
#NeuroOncology #btsm
October 18, 2025 at 9:53 AM
🧠 Great exchange at our EANO Youngsters - EORTC Joint session at #EANO2025!
🚀 We discussed how collaboration through EORTC supports early-career investigators - and vice versa - plus insights into current brain tumor trials.
Thanks @eortc.org & @eanoassociation.bsky.social!
#NeuroOncology #btsm
🚀 We discussed how collaboration through EORTC supports early-career investigators - and vice versa - plus insights into current brain tumor trials.
Thanks @eortc.org & @eanoassociation.bsky.social!
#NeuroOncology #btsm
🤩 Emeline Tabouret presenting the randomized phase II LUMEN-1 (EORTC-2334-BTG) trial on Lu-DOTATATE in recurrent meningioma at #EANO2025 - 🚀 accrual going very well!
@eortc.org @eanoassociation.bsky.social
@eortc.org @eanoassociation.bsky.social
October 18, 2025 at 7:07 AM
🤩 Emeline Tabouret presenting the randomized phase II LUMEN-1 (EORTC-2334-BTG) trial on Lu-DOTATATE in recurrent meningioma at #EANO2025 - 🚀 accrual going very well!
@eortc.org @eanoassociation.bsky.social
@eortc.org @eanoassociation.bsky.social
👏 We’re proud to see Madeline Pe, Head of EORTC #QualityofLife Department, present key insights from the SISAQOL-IMI initiative at #ESMO25.
Four years of work to improve how patient-reported outcomes are analysed in cancer trials.
📢 Catch her talk today at 14:35 in Berlin!
@qol.eortc.org
Four years of work to improve how patient-reported outcomes are analysed in cancer trials.
📢 Catch her talk today at 14:35 in Berlin!
@qol.eortc.org
October 17, 2025 at 11:52 AM
👏 We’re proud to see Madeline Pe, Head of EORTC #QualityofLife Department, present key insights from the SISAQOL-IMI initiative at #ESMO25.
Four years of work to improve how patient-reported outcomes are analysed in cancer trials.
📢 Catch her talk today at 14:35 in Berlin!
@qol.eortc.org
Four years of work to improve how patient-reported outcomes are analysed in cancer trials.
📢 Catch her talk today at 14:35 in Berlin!
@qol.eortc.org
EMA-EORTC-Workshop unterstreicht wichtige Rolle der patientenberichteten Endpunkte (PROs) für die Bewertung von Krebsmedikamenten
Die Resultate des Workshops wurden in einem Artikel in The Lancet Oncology veröffentlicht.
Unsere Meldung […]
[Original post on wisskomm.social]
Die Resultate des Workshops wurden in einem Artikel in The Lancet Oncology veröffentlicht.
Unsere Meldung […]
[Original post on wisskomm.social]
April 16, 2025 at 2:32 PM
EMA-EORTC-Workshop unterstreicht wichtige Rolle der patientenberichteten Endpunkte (PROs) für die Bewertung von Krebsmedikamenten
Die Resultate des Workshops wurden in einem Artikel in The Lancet Oncology veröffentlicht.
Unsere Meldung […]
[Original post on wisskomm.social]
Die Resultate des Workshops wurden in einem Artikel in The Lancet Oncology veröffentlicht.
Unsere Meldung […]
[Original post on wisskomm.social]
Authors report the outcome of pts enrolled in the EORTC 58081, comparing these results overall & by predefined subgroups w/ those obtained for the PRED arm of the previous EORTC 58951 & evaluated prognostic importance of the MRD level at the end of induction in EORTC 58081‘‰https://bit.ly/3VpohlB
December 9, 2024 at 9:01 AM
Authors report the outcome of pts enrolled in the EORTC 58081, comparing these results overall & by predefined subgroups w/ those obtained for the PRED arm of the previous EORTC 58951 & evaluated prognostic importance of the MRD level at the end of induction in EORTC 58081‘‰https://bit.ly/3VpohlB
Latest Analysis from the EORTC-1219/DAHANCA-29 trial
@eortc.org
oncodaily.com/voices/eortc...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EORTC
@eortc.org
oncodaily.com/voices/eortc...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EORTC
Latest Analysis from the EORTC-1219/DAHANCA-29 trial - OncoDaily
Latest Analysis from the EORTC-1219/DAHANCA-29 trial / cancer, EORTC, EORTC-1219/DAHANCA-29 trial, OncoDaily, Oncology
oncodaily.com
October 10, 2025 at 11:04 PM
Latest Analysis from the EORTC-1219/DAHANCA-29 trial
@eortc.org
oncodaily.com/voices/eortc...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EORTC
@eortc.org
oncodaily.com/voices/eortc...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EORTC
🤝 EORTC #PatientDays kicks off today in Brussels!
Patients, caregivers & advocates meet Europe’s top cancer researchers to shape better treatment, care & quality of life.
🔗 Learn more: www.eortc.org/event/patien...
#CancerResearch #Oncology #ClinicalTrials
Patients, caregivers & advocates meet Europe’s top cancer researchers to shape better treatment, care & quality of life.
🔗 Learn more: www.eortc.org/event/patien...
#CancerResearch #Oncology #ClinicalTrials
November 6, 2025 at 9:01 AM
🤝 EORTC #PatientDays kicks off today in Brussels!
Patients, caregivers & advocates meet Europe’s top cancer researchers to shape better treatment, care & quality of life.
🔗 Learn more: www.eortc.org/event/patien...
#CancerResearch #Oncology #ClinicalTrials
Patients, caregivers & advocates meet Europe’s top cancer researchers to shape better treatment, care & quality of life.
🔗 Learn more: www.eortc.org/event/patien...
#CancerResearch #Oncology #ClinicalTrials
#BBOT BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
https://www.stocktitan.net/news/BBOT/bbot-announces-poster-presentations-at-the-2025-aacr-nci-eortc-geyobqkx2iml.html
https://www.stocktitan.net/news/BBOT/bbot-announces-poster-presentations-at-the-2025-aacr-nci-eortc-geyobqkx2iml.html
BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) announced two poster presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct 22–26, 2025 in Boston.Two abstracts: BBO-11818, an oral non-covalent pan-KRAS(ON)/(OFF) inhibitor showing robust anti-tumor activity in KRAS-mutant preclinical models, will be presented in Poster Session A on Oct 23, 12:30–4:00 PM ET by Carlos Stahlhut, PhD. BBO-10203, a first-in-class oral breaker of the RAS:PI3Kα interaction that inhibited tumor growth without inducing hyperglycemia in KRAS mutant models, will be presented in Poster Session C on Oct 25, 12:30–4:00 PM ET by Kerstin Sinkevicius, PhD. Abstracts are available on the AACR website.
www.stocktitan.net
October 13, 2025 at 8:05 PM
#BBOT BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
https://www.stocktitan.net/news/BBOT/bbot-announces-poster-presentations-at-the-2025-aacr-nci-eortc-geyobqkx2iml.html
https://www.stocktitan.net/news/BBOT/bbot-announces-poster-presentations-at-the-2025-aacr-nci-eortc-geyobqkx2iml.html
#MAIA MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
https://www.stocktitan.net/news/MAIA/maia-biotechnology-presents-trial-in-progress-poster-at-the-2025-2xwr8bs75cvc.html
https://www.stocktitan.net/news/MAIA/maia-biotechnology-presents-trial-in-progress-poster-at-the-2025-2xwr8bs75cvc.html
MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted
www.stocktitan.net
October 27, 2025 at 2:45 PM
#MAIA MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
https://www.stocktitan.net/news/MAIA/maia-biotechnology-presents-trial-in-progress-poster-at-the-2025-2xwr8bs75cvc.html
https://www.stocktitan.net/news/MAIA/maia-biotechnology-presents-trial-in-progress-poster-at-the-2025-2xwr8bs75cvc.html
🏃♀️🏃♂️ Congratulations to the EORTC runners who completed the 20 Km of Brussels yesterday!
Your dedication, team spirit, and endurance reflect the same energy we bring to our mission every day.
Well done! 👏
#CancerResearch #ClinicalTrials #Oncology #20kmdeBruxelles
Your dedication, team spirit, and endurance reflect the same energy we bring to our mission every day.
Well done! 👏
#CancerResearch #ClinicalTrials #Oncology #20kmdeBruxelles
May 26, 2025 at 2:45 PM
🏃♀️🏃♂️ Congratulations to the EORTC runners who completed the 20 Km of Brussels yesterday!
Your dedication, team spirit, and endurance reflect the same energy we bring to our mission every day.
Well done! 👏
#CancerResearch #ClinicalTrials #Oncology #20kmdeBruxelles
Your dedication, team spirit, and endurance reflect the same energy we bring to our mission every day.
Well done! 👏
#CancerResearch #ClinicalTrials #Oncology #20kmdeBruxelles
🎉📊 Congratulations to EORTC research fellow Maria Chiara and RTQA Manager Sarah Kelly for presenting the latest results of the QUARTET project during a special session at the SIOPEurope25 Congress yesterday in Budapest.
May 14, 2025 at 7:53 AM
🎉📊 Congratulations to EORTC research fellow Maria Chiara and RTQA Manager Sarah Kelly for presenting the latest results of the QUARTET project during a special session at the SIOPEurope25 Congress yesterday in Budapest.
💡It’s a pleasure to welcome the EORTC Early Career Investigators to our headquarters for the launch of the ECI course.
EORTC #YECIs have access to a global network of researchers and benefit from tailored educational programmes like this one.
👉https://www.eortc.org/early-career/
EORTC #YECIs have access to a global network of researchers and benefit from tailored educational programmes like this one.
👉https://www.eortc.org/early-career/
May 6, 2025 at 12:21 PM
💡It’s a pleasure to welcome the EORTC Early Career Investigators to our headquarters for the launch of the ECI course.
EORTC #YECIs have access to a global network of researchers and benefit from tailored educational programmes like this one.
👉https://www.eortc.org/early-career/
EORTC #YECIs have access to a global network of researchers and benefit from tailored educational programmes like this one.
👉https://www.eortc.org/early-career/
Register by September 22 to get the lowest rates for the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (October 22-26; Boston), chaired by Ryan B. Corcoran, Tim F. Greten, and Elena Garralda. Learn more:
buff.ly/0ZizQBA
#Targets25
buff.ly/0ZizQBA
#Targets25
September 5, 2025 at 5:04 PM
Register by September 22 to get the lowest rates for the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (October 22-26; Boston), chaired by Ryan B. Corcoran, Tim F. Greten, and Elena Garralda. Learn more:
buff.ly/0ZizQBA
#Targets25
buff.ly/0ZizQBA
#Targets25
Experiences with the development of an EORTC source vocabulary to represent QoL questionnaire data in OMOP #OHDSISocialShowcase #JoinTheJourney
Lead: Vlad Korsik
Team: M Rahozhkina, S van Sandijk, P Prinsen, M Van Hemelrijck, C Moss
Poster: https://loom.ly/5gjg1NY
Lead: Vlad Korsik
Team: M Rahozhkina, S van Sandijk, P Prinsen, M Van Hemelrijck, C Moss
Poster: https://loom.ly/5gjg1NY
September 18, 2025 at 8:01 AM
Experiences with the development of an EORTC source vocabulary to represent QoL questionnaire data in OMOP #OHDSISocialShowcase #JoinTheJourney
Lead: Vlad Korsik
Team: M Rahozhkina, S van Sandijk, P Prinsen, M Van Hemelrijck, C Moss
Poster: https://loom.ly/5gjg1NY
Lead: Vlad Korsik
Team: M Rahozhkina, S van Sandijk, P Prinsen, M Van Hemelrijck, C Moss
Poster: https://loom.ly/5gjg1NY
Dr. Michael Jenkinson leads the meningioma research group in Liverpool, UK, which focuses on clinical trials and are developing a meningioma epilepsy programme. He is leading the international ROAM/EORTC 1308 trial (Radiation versus Observation for Atypical Meningioma) which is due to report in 2026
January 20, 2025 at 12:00 PM
Dr. Michael Jenkinson leads the meningioma research group in Liverpool, UK, which focuses on clinical trials and are developing a meningioma epilepsy programme. He is leading the international ROAM/EORTC 1308 trial (Radiation versus Observation for Atypical Meningioma) which is due to report in 2026
I’m excited to share our latest paper in Cancer treatment review about #MSI-h in #GEC 🎉
I’m grateful for have been part of the project with all these amazing experts from the #EORTC GITCG @EORTC @lizzy.smyth
Check out the full paper here doi.org/10.1016/j.ct...
#GastricCancer #immunotherapy
I’m grateful for have been part of the project with all these amazing experts from the #EORTC GITCG @EORTC @lizzy.smyth
Check out the full paper here doi.org/10.1016/j.ct...
#GastricCancer #immunotherapy
Redirecting
doi.org
February 4, 2025 at 5:37 AM
I’m excited to share our latest paper in Cancer treatment review about #MSI-h in #GEC 🎉
I’m grateful for have been part of the project with all these amazing experts from the #EORTC GITCG @EORTC @lizzy.smyth
Check out the full paper here doi.org/10.1016/j.ct...
#GastricCancer #immunotherapy
I’m grateful for have been part of the project with all these amazing experts from the #EORTC GITCG @EORTC @lizzy.smyth
Check out the full paper here doi.org/10.1016/j.ct...
#GastricCancer #immunotherapy
📈 The @eortc.org QLU-C10D is a health economic measure, and is more responsive than generic measures across various oncological settings & diagnoses.
- J. Giesinger speaking on behalf of E. Gamper at EORTC #QoLConf25
#QualityofLife #CancerResearch
- J. Giesinger speaking on behalf of E. Gamper at EORTC #QoLConf25
#QualityofLife #CancerResearch
May 12, 2025 at 11:04 AM
📈 The @eortc.org QLU-C10D is a health economic measure, and is more responsive than generic measures across various oncological settings & diagnoses.
- J. Giesinger speaking on behalf of E. Gamper at EORTC #QoLConf25
#QualityofLife #CancerResearch
- J. Giesinger speaking on behalf of E. Gamper at EORTC #QoLConf25
#QualityofLife #CancerResearch
🔚 SESSION 3 wrapped with key developments in EORTC tools for measuring HRQOL in cancer research
Thanks to @SCSodergren, Francesca Martinelli, Claire Piccinin, Hugo Vachon, Johannes Giesinger & Dagmara Kuliś
Chaired by Sally Wheelwright & Johannes Giesinger
#QoLConf25 #CancerResearch @eortc.org
Thanks to @SCSodergren, Francesca Martinelli, Claire Piccinin, Hugo Vachon, Johannes Giesinger & Dagmara Kuliś
Chaired by Sally Wheelwright & Johannes Giesinger
#QoLConf25 #CancerResearch @eortc.org
May 12, 2025 at 11:32 AM
🔚 SESSION 3 wrapped with key developments in EORTC tools for measuring HRQOL in cancer research
Thanks to @SCSodergren, Francesca Martinelli, Claire Piccinin, Hugo Vachon, Johannes Giesinger & Dagmara Kuliś
Chaired by Sally Wheelwright & Johannes Giesinger
#QoLConf25 #CancerResearch @eortc.org
Thanks to @SCSodergren, Francesca Martinelli, Claire Piccinin, Hugo Vachon, Johannes Giesinger & Dagmara Kuliś
Chaired by Sally Wheelwright & Johannes Giesinger
#QoLConf25 #CancerResearch @eortc.org
📅 Reminder: Registration is open for the @eortc.org #QualityofLife Group (QLG) autumn meeting, to be held on 25-26 September in Copenhagen!
⏰ Register by 19th August to secure your place!
🔗More info including on venue & programme: www.eortc.org/event/eortc-...
#QLGmeeting
⏰ Register by 19th August to secure your place!
🔗More info including on venue & programme: www.eortc.org/event/eortc-...
#QLGmeeting
July 22, 2025 at 7:15 AM
📅 Reminder: Registration is open for the @eortc.org #QualityofLife Group (QLG) autumn meeting, to be held on 25-26 September in Copenhagen!
⏰ Register by 19th August to secure your place!
🔗More info including on venue & programme: www.eortc.org/event/eortc-...
#QLGmeeting
⏰ Register by 19th August to secure your place!
🔗More info including on venue & programme: www.eortc.org/event/eortc-...
#QLGmeeting
This November, the EORTC Cancer Research Fund is putting patients at the heart of research.
From rare cancers to treatment optimisation, no patient is left behind.
Learn more: eortcresearchfund.org
#LeavingNoCancerPatientBehind
From rare cancers to treatment optimisation, no patient is left behind.
Learn more: eortcresearchfund.org
#LeavingNoCancerPatientBehind
November 6, 2025 at 1:46 PM
This November, the EORTC Cancer Research Fund is putting patients at the heart of research.
From rare cancers to treatment optimisation, no patient is left behind.
Learn more: eortcresearchfund.org
#LeavingNoCancerPatientBehind
From rare cancers to treatment optimisation, no patient is left behind.
Learn more: eortcresearchfund.org
#LeavingNoCancerPatientBehind
Exploring the integration of patient-reported outcome measures in clinical practice: A cross-sectional survey of EORTC healthcare professionals.
www.sciencedirect.com/science/arti...
#CancerCare #CancerResearch #PallOnc
www.sciencedirect.com/science/arti...
#CancerCare #CancerResearch #PallOnc
March 7, 2025 at 3:26 AM
Exploring the integration of patient-reported outcome measures in clinical practice: A cross-sectional survey of EORTC healthcare professionals.
www.sciencedirect.com/science/arti...
#CancerCare #CancerResearch #PallOnc
www.sciencedirect.com/science/arti...
#CancerCare #CancerResearch #PallOnc
bionetworks Trending: Step Pharma to spotlight work in CTPS2-null solid tumours at 2025 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics https://zpr.io/RCu5pcnySu28
October 21, 2025 at 9:19 AM
bionetworks Trending: Step Pharma to spotlight work in CTPS2-null solid tumours at 2025 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics https://zpr.io/RCu5pcnySu28